Who
Julie Hambleton
Director
Company insider
Files Form 4 as: Director, Erasca; Director, IGM Biosciences; Director, SpringWorks Therapeutics; SVP, Chief Medical Officer, IDEAYA Biosciences; EVP & Chief Medical Officer, Five Prime Therapeutics.
In numbers
- Trades disclosed
- 61
- Buys
- 6
- Sells
- 9
- Bought
- $210K
- Sold
- $2.3M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 18 Sep 2013
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 14 Aug 2025filed 14 Aug 2025 | IGM Biosciences | SEC FORM 4 Code D | —2,000 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,668 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,318 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,216 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —14,155 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 14 May 2025filed 15 May 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —10,060 at $0.00 | filing |
| 10 Feb 2025filed 12 Feb 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code M | —13,774 at $0.00 | filing |
| 10 Feb 2025filed 12 Feb 2025 | SpringWorks Therapeutics | SEC FORM 4 Code M | $444K13,774 at $32.27 | filing |
| 10 Feb 2025filed 12 Feb 2025 | SpringWorks Therapeutics | SEC FORM 4 Sold | $730K13,774 at $53.01 | filing |
| 25 Jul 2024filed 29 Jul 2024 | IGM Biosciencesoption or derivative | SEC FORM 4 Code M | —15,132 at $0.00 | filing |
| 25 Jul 2024filed 29 Jul 2024 | IGM Biosciences | SEC FORM 4 Code M | $21K15,132 at $1.39 | filing |
| 25 Jul 2024filed 29 Jul 2024 | IGM Biosciences | SEC FORM 4 Sold | $212K15,132 at $14.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | SpringWorks Therapeutics | SEC FORM 4 Sold | $116K2,946 at $39.41 | filing |
| 3 Jun 2024filed 5 Jun 2024 | SpringWorks Therapeutics | SEC FORM 4 Sold | $30K751 at $40.57 | filing |
| 3 Jun 2024filed 5 Jun 2024 | SpringWorks Therapeutics | SEC FORM 4 Sold | $39K931 at $41.49 | filing |
| 3 Jun 2024filed 5 Jun 2024 | SpringWorks Therapeutics | SEC FORM 4 Sold | $84220 at $42.09 | filing |
News
No headline names them, or the companies they trade most, lately.